ADCs were the dominant targeted therapy class in ASCO 2026, with the number of oral presentations increasing from 6.5% in 2024 to 11.2% in 2026. Over half of these presentations featured registrational Phase III data, with domestic Chinese ADC candidates accounting for 45% of global clinical development, making ADCs the leading area of innovation for domestic Chinese pharmaceutical companies.
This antibody-drug conjugate competitive landscape analysis was built with AI-powered workflows in Eureka LS. The platform fuses patents, literature, and molecular data into a structured report in minutes.

Executive Summary
The antibody-drug conjugate competitive landscape has become one of the most contested fields in oncology. As of June 2026, the Patsnap Eureka pharma-intelligence stack returns 2,868 antibody-drug conjugate (ADC) drug records. It also surfaces 1,293 ADC-tagged patents filed since January 2023 and 1,519 ongoing Phase 2/3 trials globally. Approvals span 20 marketed assets across HER2, Trop-2, Nectin-4, BCMA, FOLR1, CD19, CD22, CD30, CD33, CD79b, c-Met, CD123, and tissue factor. Furthermore, the past 24 months brought five new launches, including Trastuzumab Rezetecan (Hengrui), Telisotuzumab Vedotin (AbbVie), Datopotamab Deruxtecan (Daiichi/AstraZeneca), Sacituzumab Tirumotecan (Kelun/Merck), and Pivekimab Sunirine (AbbVie). Meanwhile, the field saw the largest oncology M&A of the decade — Pfizer’s $43B acquisition of Seagen (closed December 2023) — alongside AbbVie’s $10.1B ImmunoGen buyout (closed February 2024). Together, Daiichi Sankyo, AstraZeneca, AbbVie, Pfizer, Roche, Merck, Gilead, GSK, Hengrui, and Kelun drive most of the approved revenue.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.
Arena Overview
Pipeline by Payload Class
ADC pipeline by payload (2,868 total records) — Three payload classes dominate the antibody-drug conjugate competitive landscape. First, topoisomerase I inhibitors (DXd, T030, exatecan derivatives) anchor the modern wave. Notable assets include Trastuzumab Deruxtecan, Datopotamab Deruxtecan, Sacituzumab Govitecan, Sacituzumab Tirumotecan, and Trastuzumab Rezetecan. Second, microtubule inhibitors (MMAE, MMAF, DM1, DM4, soravtansine) anchor first-generation chemistry. Approved examples include Brentuximab Vedotin, Enfortumab Vedotin, Polatuzumab Vedotin, Tisotumab Vedotin, T-DM1, Disitamab Vedotin, Belantamab Mafodotin, and Mirvetuximab Soravtansine. Third, DNA-damaging payloads (calicheamicin, PBD, tesirine) cover hematologic ADCs such as Gemtuzumab Ozogamicin, Inotuzumab Ozogamicin, and Loncastuximab Tesirine.
Patent Activity and Geographic Split
ADC patent activity (2023–2026) — 1,293 ADC-tagged patents have been filed since January 2023. GeneQuantum (Suzhou) leads the 150-patent sample with 6 filings. Kelun Biotech follows with 5 filings, Gilead has 5, Duality Biologics has 4, Seagen has 4, and Cidara has 4. Synaffix, Sutro Biopharma, Zymeworks, Hangzhou Huadong, and Hengrui round out the top 12. As a result, Chinese assignees account for roughly 35% of the 150-patent sample. Meanwhile, US and Japanese originators still dominate the approved-product roster.
Player Summary Table — Tier 1 & Tier 2
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Daiichi Sankyo / AstraZeneca | JP/UK | T1 (Leader) | DXd topoisomerase I ADC | Trastuzumab Deruxtecan (2019), Datopotamab Deruxtecan (2024-12), Ifinatamab Deruxtecan (B7-H3, pipeline); 3 of 150 sampled 2023+ patents |
| Pfizer (ex-Seagen) | US | T1 (Leader) | MMAE microtubule ADC | Brentuximab Vedotin (2011), Enfortumab Vedotin (2019), Tisotumab Vedotin (2021), Inotuzumab Ozogamicin (2017); $43B Seagen acquisition closed Dec 2023 |
| AbbVie (ex-ImmunoGen) | US | T1 (Leader) | Maytansinoid + auristatin ADC | Mirvetuximab Soravtansine (2022), Telisotuzumab Vedotin (2025-05), Pivekimab Sunirine (2026-05); $10.1B ImmunoGen acquisition closed Feb 2024 |
| Roche / Genentech | CH/US | T1 (Leader) | Maytansinoid + MMAE ADC | T-DM1 (2013), Polatuzumab Vedotin (2019) |
| Merck (MSD) | US | T1 (Leader) | Trop-2 / HER3 ADC partnerships | Sacituzumab Tirumotecan (2024-11) Kelun co-development; Patritumab Deruxtecan partnership with Daiichi |
| Gilead Sciences | US | T1 (Leader) | Trop-2 ADC | Sacituzumab Govitecan (2020); 5 of 150 sampled 2023+ patents |
| Astellas Pharma | JP | T1 (Leader) | Nectin-4 MMAE ADC | Enfortumab Vedotin co-developed with Seagen/Pfizer; bladder-cancer franchise leader |
| GSK | UK | T2 (Challenger) | BCMA MMAF ADC | Belantamab Mafodotin (2020); 2024 DREAMM-7 readout drove relisting |
| Jiangsu Hengrui Pharma | CN | T2 (Challenger) | HER2 / TROP2 / B7-H3 / Nectin-4 ADCs | Trastuzumab Rezetecan (2025-05); 3 of 150 sampled 2023+ patents |
| Sichuan Kelun-Botai (Kelun Biotech) | CN | T2 (Challenger) | Trop-2 / HER2 ADC | Sacituzumab Tirumotecan (Merck partnership), Trastuzumab Botidotin (2025-10); 5 of 150 sampled 2023+ patents |
| RemeGen | CN | T2 (Challenger) | HER2 MMAE ADC | Disitamab Vedotin (2021) HER2-low gastric/urothelial; Seagen ex-Asia license |
| ADC Therapeutics | CH | T2 (Challenger) | PBD-dimer ADC | Loncastuximab Tesirine (2021) for B-cell lymphoma; pure-play PBD-payload company |
Player Summary Table — Tier 3 & Watchlist
| Player | Region | Tier | Primary Route | Key Evidence |
|---|---|---|---|---|
| Duality Biologics | CN | T3 (Follower) | HER2 / Trop-2 / B7-H3 ADCs | BNT323 (BioNTech partnership), DB-1303; 4 of 150 sampled 2023+ patents |
| GeneQuantum Healthcare | CN | T3 (Follower) | iLDC ADC platform | 6 of 150 sampled 2023+ patents — highest filing-count platform biotech |
| Synaffix | NL | T3 (Follower) | GlycoConnect site-specific conjugation | Acquired by Lonza 2023; powering multiple licensee programs |
| Lepu Biopharma / Miracogen | CN | Watchlist | EGFR MMAE ADC | Becotatug Vedotin (2025-10) — first EGFR ADC approved globally |
| LegoChem Biosciences (Ligachem) | KR | Watchlist | Conjugation linker platform | 2 of 150 sampled 2023+ patents; Janssen-licensed Trop-2 ADC LCB-84 |
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Route Differentiation Analysis
Five primary technology routes define the current ADC competitive landscape. Importantly, strength levels are evidence-backed by approved labels, clinical-stage data, and patent activity.
Route × Player Matrix
| Player | Topo I (DXd / SN-38) | Microtubule (MMAE/MMAF/DM1) | DNA-damaging (PBD/calicheamicin) | Site-specific platform | Bispecific / dual-payload ADC |
|---|---|---|---|---|---|
| Daiichi Sankyo / AstraZeneca | Strong — T-DXd, Dato-DXd, I-DXd | Absent | Absent | Moderate — DXd linker | Emerging — pipeline filings |
| Pfizer (ex-Seagen) | Absent | Strong — Brentuximab, Enfortumab, Tisotumab Vedotin | Moderate — Inotuzumab Ozogamicin | Moderate — vc-MMAE chemistry | Emerging — multispecific filings |
| AbbVie (ex-ImmunoGen) | Absent | Strong — Mirvetuximab, Telisotuzumab Vedotin | Emerging — Pivekimab Sunirine PBD-IGN | Strong — IGN linker, sulfo-SPDB | Absent |
| Roche / Genentech | Absent | Strong — T-DM1, Polatuzumab Vedotin | Absent | Moderate — internal scaffolds | Absent |
| Merck (MSD) | Strong — Sacituzumab Tirumotecan, Patritumab Deruxtecan | Absent | Absent | Absent | Absent |
| Gilead | Strong — Sacituzumab Govitecan | Absent | Absent | Absent | Emerging — Trop-2 next-gen |
| GSK | Absent | Strong — Belantamab Mafodotin (MMAF) | Absent | Absent | Absent |
| Astellas | Absent | Strong — Enfortumab Vedotin (with Seagen) | Absent | Absent | Absent |
| Hengrui | Strong — Trastuzumab Rezetecan | Emerging — Nectin-4 ADC | Absent | Absent | Emerging — bispecific ADC filings |
| Kelun-Botai | Strong — SKB264 (Sacituzumab Tirumotecan) | Emerging — HER2 vedotin | Absent | Absent | Absent |
| RemeGen | Absent | Strong — Disitamab Vedotin | Absent | Absent | Absent |
| ADC Therapeutics | Absent | Absent | Strong — Loncastuximab Tesirine PBD | Absent | Absent |
| Duality Biologics | Moderate — DB-1303 HER2 Topo I | Absent | Absent | Absent | Emerging — DB-1311 B7-H3 |
| GeneQuantum | Emerging — iLDC platform | Absent | Absent | Strong — site-specific iLDC | Emerging |
| Synaffix / Lonza | Absent | Absent | Absent | Strong — GlycoConnect | Absent |
Route concentration observations:
Concentration Takeaways
- Topoisomerase I (DXd) ADCs are the dominant payload class of the current generation. Specifically, Daiichi Sankyo’s DXd platform anchors three approved assets (T-DXd, Dato-DXd, and the Patritumab/Ifinatamab pipeline). Meanwhile, Merck-Kelun’s Sacituzumab Tirumotecan and Hengrui’s Trastuzumab Rezetecan have validated the route in China-led launches. As a result, DXd-class chemistry now sets the efficacy benchmark in HER2-low breast cancer, Trop-2 NSCLC, and HER3 NSCLC.
- Microtubule-payload ADCs (MMAE, MMAF, DM1, soravtansine) cover the broadest installed base. Pfizer-Seagen, AbbVie-ImmunoGen, Astellas, RemeGen, and Roche all anchor microtubule franchises. However, real-world data continues to show ocular and hematologic toxicity, which has narrowed indication expansion.
- DNA-damaging ADCs (PBD, calicheamicin) remain hematology-focused. Pfizer’s Inotuzumab Ozogamicin and ADC Therapeutics’ Loncastuximab Tesirine cover B-cell malignancies. Notably, AbbVie’s Pivekimab Sunirine (CD123-PBD) reached approval on 2026-05-27 for blastic plasmacytoid dendritic cell neoplasm and AML.
- Site-specific conjugation platforms form the deepest moat for next-generation ADCs. GeneQuantum (iLDC), Synaffix (GlycoConnect, acquired by Lonza in 2023), Sutro Biopharma (XpressCF), and LegoChem all license their conjugation chemistry to multiple programs. Therefore, downstream royalty economics could compound across pipelines.
- Bispecific and dual-payload ADCs are emerging. For example, BiTE-style HER2×CD3 ADCs and HER2-EGFR dual ADCs appear in 2024–2025 patent filings from Daiichi Sankyo, Hengrui, and Pfizer. Yet none have reached pivotal trials, so this route remains preclinical-to-early-clinical.
Top Player Deep Dives
1. Daiichi Sankyo / AstraZeneca (Tier 1 — Leader)
Primary route: DXd topoisomerase I ADC franchise. Key approved products: Trastuzumab Deruxtecan (Enhertu, 2019-12) for HER2+ and HER2-low breast cancer, gastric cancer, and HER2-mutant NSCLC. Datopotamab Deruxtecan (Datroway, 2024-12) for HR+/HER2− breast cancer. Pipeline: Patritumab Deruxtecan (HER3-DXd) for EGFR-mutant NSCLC. Ifinatamab Deruxtecan (B7-H3-DXd) for small cell lung cancer. Differentiation: The DXd payload combines a high drug-antibody ratio with a stable maleimide-tetrapeptide linker. As a result, T-DXd has redefined HER2-low breast cancer treatment. Trajectory: Daiichi Sankyo plus AstraZeneca now hold three approved DXd ADCs and at least four pivotal-stage candidates. Key risk: Interstitial lung disease (ILD) signal across the DXd class continues to demand mitigation strategies.
Daiichi Sankyo / AstraZeneca DXd franchise comparison:
| Product | Targets | Indication | Approval | Strategic role |
|---|---|---|---|---|
| Trastuzumab Deruxtecan (Enhertu) | HER2 × Topo I | HER2+/HER2-low breast, gastric, NSCLC | 2019-12 | Class-defining HER2 ADC |
| Datopotamab Deruxtecan (Datroway) | Trop-2 × Topo I | HR+/HER2− and TNBC breast cancer | 2024-12 | Trop-2 frontier vs Sacituzumab |
| Patritumab Deruxtecan | HER3 × Topo I | EGFR-mutant NSCLC (filed) | Pipeline | HER3 first-in-class candidate |
| Ifinatamab Deruxtecan | B7-H3 × Topo I | Small cell lung cancer (Phase 3) | Pipeline | B7-H3 SCLC opportunity |
2. Pfizer (ex-Seagen) (Tier 1 — Leader)
Primary route: MMAE microtubule ADC franchise built on Seagen’s vc-MMAE platform. Key approved products: Brentuximab Vedotin (Adcetris, 2011) for Hodgkin lymphoma. Enfortumab Vedotin (Padcev, 2019, with Astellas) for urothelial carcinoma. Tisotumab Vedotin (Tivdak, 2021, with Genmab) for cervical cancer. Inotuzumab Ozogamicin (Besponsa, 2017) for B-ALL. Differentiation: Pfizer closed the $43B Seagen acquisition in December 2023, which gave it the deepest installed MMAE pipeline in the antibody-drug conjugate competitive landscape. Trajectory: Padcev now sits at the front line of urothelial carcinoma in combination with pembrolizumab. As a result, Pfizer is leveraging Seagen’s vc-MMAE chemistry across solid-tumor expansion programs. Key risk: Microtubule payloads face ocular toxicity and competition from DXd-class agents in HER2 and Trop-2 indications.
3. AbbVie (ex-ImmunoGen) (Tier 1 — Leader)
Primary route: Maytansinoid plus auristatin ADCs anchored by ImmunoGen’s IGN linker chemistry. Key approved products: Mirvetuximab Soravtansine (Elahere, 2022) for FRα-positive ovarian cancer. Telisotuzumab Vedotin (Emrelis, 2025-05) for c-Met overexpressing NSCLC. Pivekimab Sunirine (Imitamune, 2026-05) for blastic plasmacytoid dendritic cell neoplasm and AML. Differentiation: AbbVie closed the $10.1B ImmunoGen acquisition in February 2024. The deal added the IGN PBD-class payload and sulfo-SPDB linker to the AbbVie pipeline. Trajectory: AbbVie now competes head-on with Pfizer-Seagen in the MMAE niche. Furthermore, the Pivekimab approval has revived interest in PBD chemistry for hematologic targets. Key risk: The first-generation maytansinoid ADCs (T-DM1 archetype) face DXd-class displacement; AbbVie must demonstrate IGN-class differentiation in head-to-head data.
4. Roche / Genentech (Tier 1 — Leader)
Primary route: Maytansinoid and MMAE microtubule ADCs. Key approved products: Trastuzumab Emtansine (Kadcyla, 2013) for HER2+ breast cancer. Polatuzumab Vedotin (Polivy, 2019) for diffuse large B-cell lymphoma. Differentiation: Polivy plus R-CHP became standard front-line therapy for high-risk DLBCL after the POLARIX trial. Trajectory: Kadcyla and Polivy together still drive multi-billion-dollar revenue. However, Roche has not added a new ADC franchise since 2019. Key risk: T-DM1 faces direct displacement by Trastuzumab Deruxtecan in the metastatic HER2+ setting. Therefore, Roche’s growth depends on next-generation conjugates currently in patent-stage filings.
5. Merck (MSD) (Tier 1 — Leader)
Primary route: ADC partnerships across Trop-2, HER3, and B7-H3. Key approved products: Sacituzumab Tirumotecan (Yikai-Da/Trodelvy successor, 2024-11, with Kelun-Botai) for breast and lung cancers. Pipeline: Patritumab Deruxtecan partnership with Daiichi Sankyo. Furthermore, Merck holds multiple Kelun co-development assets for ex-China rights. Differentiation: Unlike the Tier-1 owner-developers, Merck’s ADC strategy is partnership-led. As a result, the company can layer ADC franchises onto pembrolizumab combination strategies without owning conjugation chemistry. Trajectory: Merck has positioned itself to lead chemo-IO ADC combination launches by 2027. Key risk: Partnership economics reduce per-asset margin compared with owned platforms.
6. Gilead Sciences (Tier 1 — Leader)
Primary route: Trop-2 ADC franchise. Key approved product: Sacituzumab Govitecan (Trodelvy, 2020) for triple-negative breast cancer and HR+/HER2− breast cancer. Pipeline: 5 of 150 sampled 2023+ ADC patents — covering linker chemistry and next-generation Trop-2 conjugates. Differentiation: Trodelvy was the first Trop-2 ADC approved globally. As a result, Gilead holds first-mover advantage in metastatic TNBC. Trajectory: Trodelvy faces direct competition from Datopotamab Deruxtecan and Sacituzumab Tirumotecan. Therefore, Gilead is investing in next-generation Trop-2 chemistry to defend share. Key risk: Trodelvy’s neutropenia profile remains a meaningful tolerability barrier.
7. Hengrui / Kelun-Botai (Tier 2 — Challenger)
Primary route: China-originated HER2, Trop-2, B7-H3, and Nectin-4 ADCs. Key approved products: Trastuzumab Rezetecan (Hengrui, 2025-05) for HER2+ breast cancer and HER2-mutant NSCLC. Sacituzumab Tirumotecan (Kelun, partnered with Merck, 2024-11). Trastuzumab Botidotin (Kelun, 2025-10). Differentiation: Combined Hengrui plus Kelun-Botai filings represent 8 of 150 sampled 2023+ ADC patents. Together, they form the largest China-led ADC platform footprint. Trajectory: Both companies have multi-billion-dollar ex-China licensing economics with Merck and other Western partners. Key risk: Geopolitical pressure on China-to-US biotech licensing — including BIOSECURE-style legislation — could slow ex-China deal flow.
BD Deals & Strategic Moves
Business development activity has reshaped the antibody-drug conjugate competitive landscape between 2022 and 2026. The pattern is clear: Western big pharma is paying premium upfronts for de-risked Chinese ADC assets, while platform M&A consolidates conjugation chemistry under fewer owners.
2022–2026 Deal Timeline
| Date | Deal | Parties | Type | Significance |
|---|---|---|---|---|
| 2022-12 | Sacituzumab Tirumotecan ex-China license | Kelun-Botai → Merck (MSD) | Out-license | Up to $9.5B in disclosed value across multiple ADC assets; defining China-to-US ADC megadeal |
| 2023-03 | Seagen acquisition announced | Seagen → Pfizer | Acquisition | $43B all-cash; closed Dec 2023; largest oncology deal of the decade |
| 2023-04 | Synaffix acquisition | Synaffix → Lonza | Acquisition | ~$108M upfront plus milestones; consolidates GlycoConnect site-specific chemistry |
| 2023-10 | Datopotamab Deruxtecan + AZ co-development expansion | Daiichi Sankyo + AstraZeneca | Partnership | $22B-class collaboration extends DXd platform across multiple targets |
| 2023-11 | ImmunoGen acquisition announced | ImmunoGen → AbbVie | Acquisition | $10.1B; closed Feb 2024; adds IGN PBD chemistry plus Mirvetuximab Soravtansine |
| 2023-12 | BNT323/DB-1303 license | Duality Biologics → BioNTech | Out-license | HER2 ADC ex-China license; sets precedent for Duality’s Western pipeline |
| 2024-11 | Sacituzumab Tirumotecan FDA approval | Kelun-Botai / Merck | Regulatory | First China-originated Trop-2 ADC approval; validates Merck-Kelun BD thesis |
| 2024-12 | Datopotamab Deruxtecan FDA approval | Daiichi Sankyo / AstraZeneca | Regulatory | Datroway approval extends DXd franchise into Trop-2 breast cancer |
| 2025-05 | Trastuzumab Rezetecan approval | Hengrui | Regulatory | First Hengrui-originated ADC approval; HER2+ breast and HER2-mutant NSCLC |
| 2025-05 | Telisotuzumab Vedotin FDA approval | AbbVie | Regulatory | First c-Met overexpressing NSCLC ADC; orphan-style entry |
| 2025-10 | Trastuzumab Botidotin approval | Kelun-Botai | Regulatory | Second Kelun ADC franchise; HER2+ breast cancer |
| 2025-10 | Becotatug Vedotin approval | Lepu Biopharma / Miracogen | Regulatory | First EGFR ADC approved globally; nasopharyngeal carcinoma niche |
| 2026-05 | Pivekimab Sunirine approval | AbbVie | Regulatory | First CD123 PBD-IGN ADC; blastic plasmacytoid dendritic cell neoplasm and AML |
Strategic Pattern
Strategic pattern: Three deal archetypes now drive the ADC competitive landscape. First, mega-acquisitions consolidate ADC chemistry inside big pharma (Pfizer-Seagen, AbbVie-ImmunoGen, Lonza-Synaffix). Second, Chinese platform biotechs out-license late-stage assets at premium multiples (Kelun-Merck, Hengrui ex-China, Duality-BioNTech). Third, Daiichi Sankyo and AstraZeneca remain the pacesetters, expanding the DXd franchise across HER2, Trop-2, HER3, and B7-H3. As a result, the next 24 months should see continued consolidation pressure and at least 4–6 additional China-origin ADC approvals.
Unmet Needs & White Spaces
Three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path for new ADC programs.
| White Space | Current Coverage | Technical Value | Entry Path |
|---|---|---|---|
| Bispecific and dual-payload ADCs | Sparse — no approved bispecific ADC; Daiichi/Hengrui/Pfizer hold patent-stage filings. | High — dual targeting may overcome heterogeneous antigen expression and resistance to single-target ADCs. | HER2×EGFR, HER2×CD3, Nectin-4×Trop-2 architectures with dual or tandem payloads; partnership-driven with platform biotechs. |
| Non-oncology ADC programs (autoimmune, infectious disease) | Sparse — Cidara has 4 of 150 sampled 2023+ patents in antifungal ADC adjacent space; otherwise oncology-only. | High — selective immune-cell depletion in autoimmune disease, plus pathogen-targeted ADCs for resistant infections. | B-cell-depleting ADCs for refractory lupus, antifungal/antibacterial conjugates with novel payloads. |
| Solid-tumor ADCs beyond HER2 / Trop-2 / Nectin-4 | Sparse — most pipelines crowd onto the same five validated targets; broader solid-tumor antigen space remains under-explored. | High — antigens such as CDH6, GPC3, CLDN18.2, MUC16, and 5T4 cover large unmet patient populations. | Targeted antibody discovery paired with site-specific conjugation platforms (GeneQuantum, Synaffix, Sutro, LegoChem). |
Risks and Strategic Outlook for 2026 and Beyond
Key Risks
- HER2 / Trop-2 commoditisation: The HER2 ADC space already counts T-DXd, T-DM1, Disitamab Vedotin, Trastuzumab Rezetecan, and Trastuzumab Botidotin. Furthermore, Trop-2 has Sacituzumab Govitecan, Datopotamab Deruxtecan, and Sacituzumab Tirumotecan. As a result, pricing pressure and label competition will intensify by 2027. Differentiation now hinges on combination data with checkpoint inhibitors and on tolerability profile.
- Class-level safety signals: Interstitial lung disease (ILD) for DXd-class agents and ocular toxicity for MMAE-class agents both remain unresolved. Therefore, regulators continue to require risk-mitigation strategies and post-marketing commitments. These requirements raise development cost and slow combination-trial timelines.
- Cross-border BD volatility: Geopolitical pressure on China-to-US biotech licensing — including BIOSECURE-style legislation — could disrupt the Merck-Kelun, BioNTech-Duality, and Hengrui ex-China deal pipeline. Programs anchored to a single ex-China license carry political risk that platform biotechs do not.
- Conjugation IP density: 1,293 ADC-tagged patents filed since 2023 indicate active fence-building around linker chemistry, drug-antibody ratio control, and site-specific conjugation. As a result, freedom-to-operate analyses for new entrants are increasingly non-trivial.
Strategic Outlook
For strategic planning purposes, the safest near-term bets in the antibody-drug conjugate competitive landscape are conjugation-platform plays (Synaffix/Lonza GlycoConnect, GeneQuantum iLDC, Sutro XpressCF, LegoChem). Their value compounds across multiple licensee programs. The highest-upside, highest-risk bets sit in bispecific and dual-payload ADCs and in solid-tumor antigens beyond HER2 / Trop-2 / Nectin-4. White-space opportunities also exist in non-oncology ADCs, but they require either a delivery-platform advantage or a differentiated payload class. Finally, expect continued China-origin approval acceleration in 2026–2027, particularly in HER2, Trop-2, B7-H3, and EGFR ADCs.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
